Literature DB >> 10836717

Serotonin reuptake inhibitor fluoxetine decreases arteriolar myogenic tone by reducing smooth muscle [Ca2+]i.

Z Ungvari1, P Pacher, A Koller.   

Abstract

Previous studies showed that the serotonin reuptake inhibitor (SSRI) antidepressant fluoxetine (Prozac) dilates skeletal muscle and cerebral arterioles independent of the endothelium. We hypothesized that fluoxetine affects the contractile activity of arteriolar smooth muscle by interfering with Ca2+ signaling pathways. The effects of fluoxetine on pressure-induced tone of isolated rat skeletal muscle arterioles (approximately 110 microm) were investigated by videomicroscopy. Changes in smooth muscle [Ca2+]i were measured simultaneously by the fura-2 ratiometric method. Elevation of intraluminal pressure (from 20 to 120 mm Hg) increased (by approximately 20%) the smooth muscle calcium fluorescence ratio (R(Ca)) and resulted in a significant myogenic constriction (approximately 40%). Fluoxetine and nifedipine significantly decreased R(Ca) (by approximately 30%) and abolished pressure-induced arteriolar tone (EC50, 3.1 x 10(-6) and 6.0 x 10(-9) M, respectively). Constrictions to the L-type Ca2+ channel opener Bay K 8644 also were inhibited and abolished by increasing doses of fluoxetine (3 x 10(-6) and 10(-5) M, respectively). In the presence of 10(-5) M fluoxetine, a concentration that elicited submaximal (approximately 80%) dilation, elevation of extracellular Ca2+ concentration (from 2.5 to 15 mM) normalized R(Ca) and restored arteriolar myogenic tone. Thus, fluoxetine reduces [Ca2+]i and tone of arteriolar smooth muscle, likely by interfering with Ca2+ entry. We speculate that the "calcium antagonist" effect of fluoxetine may be an additional element in the therapeutic actions of this drug.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10836717     DOI: 10.1097/00005344-200006000-00004

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

1.  Treatment of depression in acute coronary syndromes with selective serotonin reuptake inhibitors.

Authors:  Joost P van Melle; Peter de Jonge; Maarten P van den Berg; Harm J Pot; Dirk J van Veldhuisen
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Selective serotonin reuptake inhibitors (SSRIs) inhibit insulin secretion and action in pancreatic β cells.

Authors:  Roi Isaac; Sigalit Boura-Halfon; Diana Gurevitch; Alla Shainskaya; Yechiel Levkovitz; Yehiel Zick
Journal:  J Biol Chem       Date:  2012-12-28       Impact factor: 5.157

3.  Inositol 1,4,5-trisphosphate (IP3)-mediated Ca2+ release evoked by metabotropic agonists and backpropagating action potentials in hippocampal CA1 pyramidal neurons.

Authors:  T Nakamura; K Nakamura; N Lasser-Ross; J G Barbara; V M Sandler; W N Ross
Journal:  J Neurosci       Date:  2000-11-15       Impact factor: 6.167

Review 4.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

Review 5.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

6.  Sertraline exposure leads to small left heart syndrome in adult mice.

Authors:  Sarah E Haskell; Gregory M Hermann; Benjamin E Reinking; Kenneth A Volk; Veronica A Peotta; Vivian Zhu; Robert D Roghair
Journal:  Pediatr Res       Date:  2012-12-11       Impact factor: 3.756

7.  Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants.

Authors:  Victor M Castro; Patience J Gallagher; Caitlin C Clements; Shawn N Murphy; Vivian S Gainer; Maurizio Fava; Jeffrey B Weilburg; Susanne E Churchill; Isaac S Kohane; Dan V Iosifescu; Jordan W Smoller; Roy H Perlis
Journal:  BMJ Open       Date:  2012-03-30       Impact factor: 2.692

Review 8.  Selective serotonin reuptake inhibitors and cardiovascular events: A systematic review.

Authors:  Mohammad Hassan Nezafati; Ali Eshraghi; Mohammad Vojdanparast; Saeed Abtahi; Pouya Nezafati
Journal:  J Res Med Sci       Date:  2016-09-01       Impact factor: 1.852

9.  Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.

Authors:  Melissa Cambron; Jop Mostert; Patrick Haentjens; Marie D'Hooghe; Guy Nagels; Barbara Willekens; Dorothea Heersema; Jan Debruyne; Wim Van Hecke; Luc Algoed; Nina De Klippel; Erwin Fosselle; Guy Laureys; Henri Merckx; Bart Van Wijmeersch; Ludo Vanopdenbosch; Wim Verhagen; Raymond Hupperts; Gerald Hengstman; Veronique Michiels; Annick Van Merhaegen-Wieleman; Jacques De Keyser
Journal:  Trials       Date:  2014-01-25       Impact factor: 2.279

10.  The Beta-1-Receptor Blocker Nebivolol Elicits Dilation of Cerebral Arteries by Reducing Smooth Muscle [Ca2+]i.

Authors:  Peter Cseplo; Zoltan Vamos; Ivan Ivic; Orsolya Torok; Attila Toth; Akos Koller
Journal:  PLoS One       Date:  2016-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.